Arcturus Therapeutics Holdings Inc. - ARCT STOCK NEWS

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:00 PM ET. Management team members, including CEO Joseph Payne and CFO Andrew Sassine, will present a corporate overview followed by a Q&A session. Investors can register for the presentation here. A replay will be available on Arcturus’ Investor Relations website for 90 days post-event.

Arcturus Therapeutics (NASDAQ: ARCT) announced promising findings from its Phase 1/2 booster trial for mRNA vaccine candidates ARCT-154 and ARCT-165. The study demonstrated 54-fold and 47-fold increases in neutralizing antibody titers against the Omicron variant after administering low doses (5 mcg) at least five months post-initial vaccination. This data supports expanding clinical development aimed at evaluating the candidates as effective COVID-19 booster vaccines. The ongoing trial is being conducted in the U.S. and Singapore.

Arcturus Therapeutics announced positive results from its Phase 1/2 booster study of ARCT-154 and ARCT-165 vaccines. The data showed a significant 30-fold increase in neutralizing antibody concentrations against SARS-CoV-2 at Day 15, maintained at 28-fold by Day 29. Both vaccines demonstrated strong responses against various COVID-19 variants, supporting their potential as booster options. Administered as low-dose boosters, they were well-tolerated, indicating promise in ongoing clinical development.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options totaling 5,800 shares to a new employee as part of their compensation package. The options have an exercise price of $27.21 per share, based on the closing price on January 18, 2022. They feature a ten-year term with a one-year vesting period for 25% of the shares, followed by monthly vesting over three years. This grant aligns with Nasdaq Rule 5635(c)(4) and is intended to encourage the new hire’s acceptance of employment.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced stock options grants totaling 13,800 shares to three new employees. The grants, approved by the Compensation Committee and Board, serve as an incentive for employment acceptance. The exercise price is set at $35.52, matching the closing stock price on December 15, 2021. The options vest over four years, starting with 25% after one year and the remainder monthly over the next three years, contingent on continued employment. Arcturus focuses on developing mRNA medicines and vaccines for various diseases.

Arcturus Therapeutics has reported preliminary findings from its ongoing clinical study of ARCT-154 and ARCT-165. The data reveals a significant 50-fold increase in neutralizing antibody levels against SARS-CoV-2 following a boost with ARCT-154. The vaccine candidates show activity against various variants and will be evaluated for effectiveness against the omicron variant, with initial data expected in Q1 2022. The Phase 1/2 trials are being conducted in the U.S. and Singapore, with regulatory submissions for ARCT-154 expected soon in Vietnam.

Arcturus Therapeutics (NASDAQ: ARCT) has announced the appointment of Dr. Jing Marantz, an accomplished biopharma executive, to its Board of Directors. Dr. Marantz brings extensive clinical expertise and industry experience, having held senior positions at prominent biopharma companies such as Acceleron and Alnylam Pharmaceuticals. CEO Joseph Payne expressed confidence in Dr. Marantz's ability to contribute to the advancement of Arcturus's vaccine programs, including those targeting COVID-19 and other mRNA-based therapeutic candidates.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will participate in the Piper Sandler’s 33rd Annual Virtual Healthcare Conference from November 30 to December 02, 2021. A pre-recorded fireside chat will be available on-demand starting November 22, 2021, at 10:00 a.m. ET. Founded in 2013 and based in San Diego, Arcturus specializes in mRNA medicines and vaccines, with a pipeline that includes candidates for COVID-19, influenza, and various rare diseases. The company utilizes advanced technologies like LUNAR® and STARR™ to develop innovative therapies.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options for 16 newly-hired employees, totaling 185,700 shares. The options, with an exercise price of $36.65 per share, are a part of the employment compensation package and will vest over four years. This move is in accordance with Nasdaq Rule 5635(c)(4) as an inducement for accepting employment. The stock options are contingent upon filing a Form S-8 Registration Statement, which has already been filed.